Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference

Core Viewpoint - Sera Prognostics Inc. is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information, and will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 [1] Company Overview - Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care [3] - The company aims to provide early, pivotal pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera has a robust pipeline of innovative diagnostic tests aimed at early prediction of preterm birth risk and other pregnancy complications [3] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns [4] - Over the last five years, more than one in ten infants in the United States has been born prematurely [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion for 2016 [4] PreTRM® Test Details - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test measures and analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify women at increased risk during weeks 18 through 20 of pregnancy [5] - The PreTRM® Test enables more informed, personalized clinical decisions based on each woman's individual risk [5]